Cilengitide
As of the edition of 20 October 2026, Cilengitide is a protein: stopped in 2018; acts on ITGAV.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Protein
- Registered trials
- 27, 7 stopped early
- Disease areas
- Cancer; Nervous system; Blood and lymph; Immune system; Infections; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Cilengitide.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ITGAV | Integrin alpha-V | P06756 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 11 | 9 | 0 | 2 |
| Phase 2 | 15 | 9 | 0 | 5 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 27 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck KGaA | Lead sponsor of trials | 2004 to now |